SCREENING PROGRAM Sample Clauses

SCREENING PROGRAM. The parties agree that the first Target shall be TGF beta receptor Type I. Upon designation of any additional Target by CUSTOMER, NeoGenesis will have [*] to agree to conduct the control and follow up control experiments of para. 2 of ATTACHMENT A with that Target or to reject (because of its unavailability) the Target. Upon such agreement, CUSTOMER shall within [*] deliver all necessary reagents with respect to such Target to NeoGenesis. NeoGenesis shall within [*] of receipt of such reagents conduct the control and follow-up experiments of para. 2 of ATTACHMENT A with respect to the Target. It will also establish an SOP as provided under that paragraph. The Program for a given Target will remain in effect for a period of [*] from the time of transfer of reagents by CUSTOMER to NeoGenesis, with an option by CUSTOMER to renew the Program for such Target for an additional [*] period on terms and conditions, including level of support, that are mutually agreeable. CUSTOMER shall notify NeoGenesis whether CUSTOMER wishes to extend the Program for a given Target for an additional [*], no later than [*] prior to termination of the initial term. NeoGenesis will apply its ALIS method to screen the NeoMorph Screening Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further * = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. evaluation and development. Alternatively, NeoGenesis shall apply ALIS screening of libraries provided by CUSTOMER as described in ATTACHMENT A. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. NeoGenesis shall conduct the screening and deliver a Final Target Report as described in ATTACHMENT A, but in any event within [*] following the date that the applicable Target is delivered to NeoGenesis, unless the parties agree in writing to extend the period for performance of the Program (the SCREENING PERIOD).
Sample 1See All (6)
AutoNDA by SimpleDocs
SCREENING PROGRAM. 13 3.1 Screening Program. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.1.1 Screening by Aurora. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.1.2
Sample 1Sample 2Sample 3
SCREENING PROGRAM. (a) NeoGenesis will apply its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. With respect to each Target delivered by OGS, NeoGenesis shall initiate its screening obligations as more particularly set out in the Program within [*] following the date of receipt of such Target and complete such screening obligations within [*] following the date it commences its screening obligations with respect to such Target, unless the parties agree in writing to extend the period for performance and except as otherwise provided in Section 2.1(a)(ii) (such period, the SCREENING PERIOD).
Sample 1Sample 2
SCREENING PROGRAM. NeoGenesis will apply use its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. NeoGenesis shall commence the Program following the date the Targets are delivered to NeoGenesis and shall complete the Program within [*] following the date that the Targets are delivered to NeoGenesis, unless the parties agree in writing to extend the period for performance of the Program (the SCREENING PERIOD).
Sample 1Sample 2
SCREENING PROGRAM. During the Screening Term, PPI will employ exclusively assays A-D as described below to screen for A(beta) peptide polymerization inhibition activity for 50,000 compounds selected and supplied by BI. *** Depending on activity levels seen in Assay A, PPI may require additional material for Assays B-D and subsequent in vivo assays. PPI will deliver to BI SAR data on existing PPI Compounds within 6 weeks of the Effective Date. BI will deliver to PPI at least 13,000, 25,000, 37,500, and 50,000 compounds within 2.0, 5.0, 12.0, and 16.0 months respectively, of the Effective Date and PPI anticipates, barring any unforeseen technical issues, screening 25,000 compounds in its Nucleation Assay within 12 months and 50,000 compounds in its Nucleation Assay within 24 months of the Effective Date. Compounds jointly designated will be further screened in secondary assays described below. Assay Functional Measurement Manpower ----- ---------------------- -------- A. Nucleation Assay *** *** FTE B. Extension Assay *** *** FTE C. Neurotoxicity *** *** FTE D. Specificity *** *** FTE PPI will make available *** FTE's to the Screening Program immediately following the Effective Date. These FTE's will either be new hires or redeployments of existing personnel. PPI anticipates that it will be evaluating BI compounds in assays A-D within 6 weeks of first receiving compounds from BI. All Applicable data will be supplied to BI in PC compatible form (e.g. ASCI II or Excel files). All BI compounds will be handled or disposed of in accordance with BI's written instructions.
Sample 1Sample 2
SCREENING PROGRAM. The Program to be performed by NeoGenesis with respect to the Targets will screen compounds contained in the NeoGenesis NeoMorph Screening Library as updated from time to time by NeoGenesis (collectively, such compounds are the Compounds).
Sample 1
SCREENING PROGRAM. During the Screening Term, PPI will employ exclusively assays A-D as described below to screen for A(beta) peptide polymerization inhibition activity for 50,000 compounds selected and supplied by BI. *** Depending on activity levels seen in Assay A, PPI may require additional material for Assays B-D and subsequent in vivo assays. PPI will deliver to BI SAR data on existing PPI Compounds within 6 weeks of the Effective Date. BI will deliver to PPI at least 13,000, 25,000, 37,500, and 50,000 compounds within 2.0, 5.0, 12.0, and 16.0 months respectively, of the Effective Date and PPI anticipates, barring any unforeseen technical issues, screening 25,000 compounds in its Nucleation Assay within 12 months and 50,000 compounds in its Nucleation Assay within 24 months of the Effective Date. Compounds jointly designated will be further screened in secondary assays described below. Assay Functional Measurement Manpower ----- ---------------------- -------- A. Nucleation Assay *** *** FTE
Sample 1
AutoNDA by SimpleDocs
SCREENING PROGRAM 
Sample 1Sample 2Sample 3See All (4)

Related to SCREENING PROGRAM

  • Training Program It is agreed that there shall be an Apprenticeship Training Program, the provisions of which are set forth in Exhibit "C", which is attached hereto and forms part of this Agreement.

  • Training Programs All employees shall successfully complete all necessary training prior to being assigned work (e.g., all employees will complete health and safety training prior to being assigned to task). Nothing in this Article or provision shall constitute a waiver of either party’s bargaining obligations or defenses. The Employer still has an obligation to notify and bargain changes in terms and conditions of employment with the exclusive representative.

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Develop programs 1) The Employer will develop and implement health promotion and health education programs, subject to the availability of resources. Each Appointing Authority will develop a health promotion and health education program consistent with the Minnesota Management & Budget policy. Upon request of any exclusive representative in an agency, the Appointing Authority shall jointly meet and confer with the exclusive representative(s) and may include other interested exclusive representatives. Agenda items shall include but are not limited to smoking cessation, weight loss, stress management, health education/self-care, and education on related benefits provided through the health plan administrators serving state employees.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Pilot Programs The Employer may develop voluntary pilot programs to test the acceptability of various risk management programs. Incentives for participation in such programs may include limited short-term improvements to the benefits outlined in this Article. Implementation of such pilot programs is subject to the review and approval of the Joint Labor-Management Committee on Health Plans.

Time is Money Join Law Insider Premium to draft better contracts faster.